Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies
Details
Publication Year 2025-06,Volume 12,Issue #6,Page e470-e481
Journal Title
Lancet Haematology
Publication Type
Commentary
Abstract
The increasing use of immunotherapeutic approaches, cellular therapies, and targeted agents is rapidly and profoundly changing the treatment paradigms of haematological malignancies. These novel therapies are increasingly incorporated into earlier lines of treatment. Some are administered for a fixed duration, often with curative intent, whereas others are administered chronically for disease control. The associated acute, mid-term, and long-term toxic effects can differ markedly from conventional cytotoxic chemotherapy and radiotherapy. Accumulating clinical experience and data enable identification of class-specific effects and development of consensus-based guidelines for toxicity management. In this third paper in the Series on adverse event reporting, we build on our emerging understanding of toxicity profiles of novel treatments to propose an actionable framework for improved assessment, reporting, and critical appraisal of treatment tolerability. We discuss recent insights regarding second cancers and the relevance of infectious complications, explore tolerability aspects of time-limited treatments, and suggest approaches to address gaps in tolerability assessment.
Publisher
Elsevier
Keywords
Humans; *Hematologic Neoplasms/therapy; *Immunotherapy/adverse effects/methods; *Molecular Targeted Therapy/adverse effects/methods; *Cell- and Tissue-Based Therapy/adverse effects/methods
Department(s)
Haematology
Open Access at Publisher's Site
https://doi.org/10.1016/s2352-3026(25)00051-1
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-06-03 07:20:19
Last Modified: 2025-06-03 07:20:41

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙